Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Otsuka Holdings Company ADR
(OP:
OTSKY
)
29.16
-0.25 (-0.85%)
Streaming Delayed Price
Updated: 12:04 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Otsuka Holdings Company ADR
Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market
↗
October 16, 2025
Bank of America initiates coverage on Vera Therapeutics, citing strong potential for atacicept, its kidney treatment.
Via
Benzinga
TANAKA to Provide Medals for the Tokyo Marathon 2025 That Represent All the Participants in the Event with Woven Lines
February 06, 2025
From
TANAKA PRECIOUS METAL GROUP Co., Ltd.
Via
JCN Newswire
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
↗
December 31, 2024
Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025.
Via
Benzinga
TANAKA to Provide Medals Representing the Event Concept with a Design of Gently Curved Circular Expansion for the Tokyo Legacy Half Marathon 2024
October 17, 2024
From
Tanaka Holdings Co., Ltd.
Via
JCN Newswire
OTSKY Stock Earnings: Otsuka Holdings Reported Results for Q2 2024
↗
August 23, 2024
Otsuka Holdings just reported results for the second quarter of 2024.
Via
InvestorPlace
OTSKY Stock Earnings: Otsuka Holdings Reported Results for Q1 2024
↗
May 17, 2024
Otsuka Holdings just reported results for the first quarter of 2024.
Via
InvestorPlace
Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
↗
August 05, 2022
Via
Benzinga
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
↗
April 16, 2024
IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo.
Via
Benzinga
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
↗
March 20, 2024
IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer's Dementia. Shows reduction in agitation vs. placebo observed.
Via
Benzinga
Regulatory Setback For Medtronic's High Blood Pressure Device - FDA Backed Japanese Firms' Similar Device For Uncontrolled Hypertension
↗
August 24, 2023
Medtronic Plc (NYSE: MDT) says the FDA Circulatory System Devices Panel (CSDP) voted unanimously (13-0) on safety and in favor (7-6) of the effectiveness of the Symplicity blood pressure procedure,
Via
Benzinga
Individuals With Uncontrolled Hypertension - FDA Adcomm Panel Just Supported Japanese MedTech's Blood Pressure Treatment Device
↗
August 23, 2023
The FDA's Circulatory Systems Devices Panel of the Medical Devices Advisory Committee backed Recor Medical Inc and its parent company, Otsuka Medical Devices Co Ltd's
Via
Benzinga
Why Are Akebia Therapeutics Shares Falling Today?
↗
May 16, 2022
Via
Benzinga
FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia
↗
March 30, 2022
Via
Benzinga
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
↗
May 11, 2023
Otsuka Pharmaceutical Co Ltd (OTC: OTSKF) (OTC: OTSKY) (Otsuka) and H.
Via
Benzinga
Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches
↗
November 03, 2022
Approximately 160,000 individuals in the United States are diagnosed with polycystic kidney disease, and the global prevalence of the condition is estimated at between 4 million and 7 million people.
Via
Benzinga
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
↗
July 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?
↗
January 31, 2022
One very large drug multinational has already been active in writing checks to finance drug development in the psychedelic drug industry.
Via
Talk Markets
4 Pre-Merger SPACs to Buy That Are Poised to Soar
↗
November 16, 2021
From quantum computing to energy storage, these four SPACs' merger partners could prove to be quite disruptive over the longer term.
Via
InvestorPlace
Topics
Electric Vehicles
Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
↗
June 01, 2021
Akebia Therapeutics Inc (NASDAQ: AKBA) and its collaborator Otsuka Holdings (OTC: OTSKY) have announced that the FDA has accepted to review vadadustat...
Via
Benzinga
3 Cheap Pharmaceutical Stocks to Grab Now
↗
May 28, 2021
The pharmaceutical industry has been the beneficiary of significant investor attention amid the COVID-19 pandemic as society turned to its products to fight the coronavirus.
Via
Talk Markets
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
